Two medicines, side by side
Bisacodyl vs prucalopride
Bisacodyl and prucalopride are both labeled for constipation. Pharmacies paid $0.320 per bisacodyl 10 mg suppository and $0.639 per prucalopride 1 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the bisacodyl FDA label on DailyMed (effective April 8, 2025); the prucalopride FDA label on DailyMed (effective July 17, 2025).
Highlights of the bisacodyl record
Bisacodyl · label of April 8, 2025
Used for
From the label: indications● for relief of occasional constipation and irregularity ● this product generally produces bowel movement in 6 to 12 hours Use ● for relief of occasional constipation and irregularity ● this product generally produces bowel movement in 6 to 12 hours
On the market
- Earliest approval on file
- n/a
- Generic labelers
- none listed
- Pharmacy cost
- $0.320 per suppository
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the prucalopride record
Prucalopride (Motegrity) · label of July 17, 2025
Used for
From the label: indicationsMOTEGRITY ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. MOTEGRITY is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
On the market
- Earliest approval on file
- December 14, 2018
- Generic labelers
- 18 labelers
- Pharmacy cost
- $0.639 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Bisacodyl label of April 8, 2025, Prucalopride label of July 17, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do bisacodyl and prucalopride differ on the record?
Generics: bisacodyl none approved; prucalopride since 2024 (Drugs@FDA).
| Bisacodyl | Prucalopride | |
|---|---|---|
| Labeled for | Constipation | Constipation |
| Pharmacologic class | n/a | Serotonin-4 Receptor Agonist |
| How it works (label) | n/a | Prucalopride, a selective serotonin type 4 (5-HT 4 ) receptor agonist, is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions [HAPCs]), which increases bowel motility. |
| Half-life (label) | n/a | n/a |
| Earliest approval on file (Drugs@FDA) | n/a | December 14, 2018 |
| First generic approved | none | December 26, 2024 |
| Generic labelers (NDC) | none listed | 18 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.320 per suppository (Bisacodyl 10 mg suppository) | $0.639 per tablet (Prucalopride 1 mg tablet) |
| 12-month price change | -4% | -95% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 14,161 | 2,617 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to bisacodyl
- every medicine labeled for the same conditions